News

June 2021

PIC/S Adapting EU GMP Annex 16 on Authorised Person and Batch Release

Geneva, 15 June 2021:

Background

EU GMP Annex 16 on Certification by a Qualified Person* and Batch Release entered into force in 2002. At the time, PIC/S did not deem it necessary to transpose this EU-specific annex for PIC/S purposes. Following the revision of EU Annex 16 in 2016, PIC/S re-discussed whether to transpose Annex 16 in order to harmonise internationally requirements regarding product release in line with PIC/S’ mission “to lead the international development, implementation and maintenance of harmonised GMP standards and quality systems of Inspectorates in the field of medicinal products”. The PIC/S Sub-Committee on GMDP Harmonisation (SCH), led by Paul Gustafson (Health Canada), was mandated to transpose a PIC/S version of EU GMP Annex 16 in accordance with a memorandum of understanding with the European Medicines Agency (EMA).

* The PIC/S term of “Authorised Person” and the EU term of “Qualified Person” are strictly equivalent.

Public consultation

Following several internal rounds of consultation and extensive discussion between PIC/S Members on draft versions of PIC/S Annex 16, the PIC/S Committee recently agreed to proceed to Step 2 of the PIC/S consultation process.  Step 2 of the PIC/S adoption process enables an opportunity for PIC/S Participating Authorities to consult with stakeholders. PIC/S Participating Authorities may take differing approaches to consultation.  Some may engage in consultation at later periods through local harmonisation efforts that realize subsequent adaptation of PIC/S GMP into jurisdictional specific GMP guides or requirements.

This consultation will be launched on 15 June 2021 for a period of 3 months. The consultation will focus on national stakeholders of non-EU/EEA Members of PIC/S, considering that EU/EEA Members of PIC/S already apply EU Annex 16.

Where the implementation of PIC/S Annex 16 will affect a jurisdiction, the competent PIC/S Participating Authority will consult pharmaceutical industry associations. This consultation may also be open to the general public and other stakeholders. Comments from stakeholders will be considered carefully while working toward a general objective of ensuring continued harmonisation and equivalence between the EU and PIC/S GMP Guides. Minimal deviations between the guides will help work toward improved global harmonisation.

International professional and industry associations, which are interested to contribute to the PIC/S consultation process, are invited to channel their consolidated comments through one of the PIC/S Participating Authorities, which will launch a public consultation. For further enquiries, please contact info@picscheme.org

August 2023

Entry into force of revised GMP Annex 1

The revised Annex 1 on “sterile manufacturing of the PIC/S GMP Guide entered into force on 25 August 2023 and has been published on https://picscheme.org/en/publications. It entered into operation the same day as the revised Annex 1 of the EU GMP Guide, which is identical with PIC/S Annex 1 (with some minor differences). The revised Annex 1 is now applicable with the exception of paragraph 8.123. This paragraph has a later date of entry into force, which is on 25 August 2024. For the background to the revision of Annex 1, see https://picscheme.org/en/news?dateselect=2022

The revised Annex 1 is an integral part of the PIC/S GMP Guide (PE 009-17), which has also been revised. The GMP Guide has 4 parts: Introduction, Part I, Part II, and Annexes. Annex 1 can be found under ‘PIC/S GMP Guide (PE 009-17) Annexes’.

August 2023

Philippines applies for PIC/S membership

Geneva, 7 August 2023: On 20 June 2023, Philippines Food and Drug Administration (FDA PH) submitted a complete membership application to PIC/S. 

The Rapporteur(s) will be appointed by written procedure.

August 2023

PIC/S Seminar 2023

Geneva, 2 August 2023: Registrations for the 2023 PIC/S Seminar on “Soft Skills that Make a Good GMP/GDP Inspector in 2023” which will be hosted by Thai FDA from 8-10 November 2023 are now open (for Medicines Regulatory Authorities only). Deadline for registration is 31 October 2023.

For more information,  please contact the PIC/S Secretariat.

June 2023

Bulgaria / BDA and Saudi Arabia / SFDA join PIC/S

Geneva, 12 June 2023:  The PIC/S Committee has invited Bulgaria’s Bulgarian Drug Agency (BDA) and Saudi Arabia’s Saudi Food and Drug Authority (SFDA) to join the PIC Scheme.

Bulgaria / BDA will become PIC/S’ 55th Participating Authority and Saudi Arabia / SFDA PIC/S 56th Participating Authority as from 1 July 2023.

BDA submitted a complete membership application in August 2018. The PIC/S assessment was combined with a Canadian MRA assessment and EMA JAP audit. A paper assessment was carried out followed by a joint tripartite PIC/S – EMA - Canada MRA on-site assessment visit which took place in February 2023, after establishment of the new system for the GMP Inspectorate of BDA [following a JAP audit in 2018]. The assessment report was finalised in April 2023. The Audit team recommended to the Committee to accept the PIC/S membership application of BDA, which was endorsed by the PIC/S Sub-Committee on Compliance (SCC). At its meeting in Geneva on 11-12 May 2023, the PIC/S Committee then unanimously accepted the membership of BDA in PIC/S as from 1 July 2023.

SFDA submitted a complete membership application in February 2020, after successfully completing the pre-accession process. This facilitated the accession process. A paper assessment was carried out followed by an on-site assessment visit which took place in March 2023. The assessment report was finalised in the course of April 2023. The Audit team recommended to the Committee to accept the PIC/S membership application of SFDA, which was endorsed by the PIC/S Sub-Committee on Compliance (SCC). At its meeting in Geneva on 11-12 May 2023, the PIC/S Committee then unanimously accepted the membership of SFDA in PIC/S as from 1 July 2023.

June 2023

Changes to the PIC/S Executive Bureau

Geneva, 12 June 2023: A new PIC/S Deputy Chairperson and a new PIC/S Sub-Committee on Strategic Development (SCSD) Chair took office on 11 May 2023. Due to the retirement from her Agency of the former PIC/S Deputy Chairperson and SCSD Chairperson, Susan Laska (US FDA), the PIC/S Committee carried out by-elections at its last meeting in Geneva on 11-12 May 2023. It unanimously elected Mr Jacques Morénas (France / ANSM) as new PIC/S Deputy Chairperson - in addition to his current position of PIC/S Sub-Committee on Training (SCT) Chair - and elected Ms Jennifer Burnett (Australia / TGA) as new PIC/S Sub-Committee on Strategic Development (SCSD) Chair. All other Executive Bureau Members remain the same.

With these changes, the new composition of the Executive Bureau for the remaining of the period 2022-2023 consists of:

  • Mr Paul Gustafson (Canada / ROEB), PIC/S Chairperson;
  • Mr Jacques Morénas (France / ANSM), PIC/S Deputy Chairperson and Chair of the Sub-Committee on Training (SCT);
  • Ms Anne Hayes (Ireland / HPRA), immediate past PIC/S Chairperson;
  • Dr Andreas Krassnigg (Austria / AGES), Chair of the Sub-Committee on Expert Circles (SCEC);
  • Mr Ger Jan van Ringen (Netherlands / IGJ), Chair of the Sub-Committee on Budget, Risk and Audit (SCB);
  • Mr Ian Jackson (UK / MHRA), Chair of the Sub-Committee on GM(D)P Harmonisation (SCH);
  • Dr Kentaro Hara (Japan / PMDA), Chair of the Sub-Committee on Communication (SC COM);
  • Mr Henning Willads Petersen (Denmark / DKMA), Chair of the Sub-Committee on Compliance (SCC); and
  • Ms Jennifer Burnett (Australia / TGA), Chair of the Sub-Committee on Strategic Development (SCSD).